Bellicum Pharmaceuticals Lands $20M

Houston-based Bellicum Pharmaceuticals, a developer of therapeutic cancer vaccines, announced today that it has raised $20M in a Series B funding round. The round included AVG Ventures and Remeditex Ventures. According to the firm, the funding is being tranched into two parts, including $10M immediately, and $10M following initiation of its next phase of clinical trials, expected in Q3. The firm also said it has received a $6.1M award from the Cancer Prevention and Research Institute of Texas (CPRIT) along with the funding. AVG Ventures' James Brown and Remeditex Ventures' Dennis Stone both join the company's board with the funding. More information »